Shenzhen Hepalink Pharmaceutical Co Ltd
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers finished dose pharmaceutical products,… Read more
Shenzhen Hepalink Pharmaceutical Co Ltd (002399) - Total Liabilities
Latest total liabilities as of September 2025: CN¥4.70 Billion CNY
Based on the latest financial reports, Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has total liabilities worth CN¥4.70 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shenzhen Hepalink Pharmaceutical Co Ltd - Total Liabilities Trend (2006–2024)
This chart illustrates how Shenzhen Hepalink Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shenzhen Hepalink Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenzhen Hepalink Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alstom PK
PINK:ALSMY
|
USA | $23.93 Billion |
|
Jiangsu SINOJIT Wind Energy Technology Co Ltd
SHG:601218
|
China | CN¥757.19 Million |
|
Medplus Health Services Limited
NSE:MEDPLUS
|
India | ₹17.28 Billion |
|
Wutong Holding Group Co Ltd
SHE:300292
|
China | CN¥918.09 Million |
|
Medco Energi Internasional Tbk
JK:MEDC
|
Indonesia | Rp6.04 Billion |
|
Chongqing Landai Powertrain Corp Ltd
SHE:002765
|
China | CN¥3.33 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Shenzhen Hepalink Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Hepalink Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual total liabilities of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥5.14 Billion | -28.74% |
| 2023-12-31 | CN¥7.22 Billion | -14.17% |
| 2022-12-31 | CN¥8.41 Billion | +10.83% |
| 2021-12-31 | CN¥7.58 Billion | +3.38% |
| 2020-12-31 | CN¥7.34 Billion | -5.59% |
| 2019-12-31 | CN¥7.77 Billion | +4.87% |
| 2018-12-31 | CN¥7.41 Billion | +34.66% |
| 2017-12-31 | CN¥5.50 Billion | +14.05% |
| 2016-12-31 | CN¥4.83 Billion | +42.95% |
| 2015-12-31 | CN¥3.38 Billion | +113.93% |
| 2014-12-31 | CN¥1.58 Billion | +674.17% |
| 2013-12-31 | CN¥203.80 Million | -5.00% |
| 2012-12-31 | CN¥214.53 Million | +257.69% |
| 2011-12-31 | CN¥59.98 Million | -42.02% |
| 2010-12-31 | CN¥103.44 Million | -66.23% |
| 2009-12-31 | CN¥306.33 Million | +13.00% |
| 2008-12-31 | CN¥271.09 Million | +143.60% |
| 2007-12-31 | CN¥111.28 Million | -56.81% |
| 2006-12-31 | CN¥257.68 Million | -- |